A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib

Inclusion Criteria:

- Age of 18 years and older.

- Chronic myeloid leukemia (CML)

- Previous treatment with imatinib at a dose of >600 mg/day AND the development of
progressive disease while receiving imatinib at that dose, OR

- CML with resistance to imatinib at a dose less than or equal to 600 mg/day with
genetic mutation in the BCR-ABL gene that is associated with a high level of
resistance to imatinib, OR

- Intolerance to imatinib at any dose

- Adequate organ function

- Women who are able to bear children must have a negative serum or urine pregnancy
test. Adequate methods of contraception must be used throughout the study to avoid
pregnancy for the entire interval of at least 1 month before and 3 months after
completion of the study medication.

Exclusion Criteria:

- Woman who are pregnant or breastfeeding

- Men whose sexual partners are women who are of childbearing potential, and who are
unwilling or unable to use an acceptable method to avoid pregnancy of his partner for
the entire study period as outlined above

- Previous diagnosis of accelerated phase or blast crisis CML.

- Participants who are eligible and willing to undergo transplantation during the
screening period

- Uncontrolled or significant cardiovascular disease

- Use of imatinib within 7 days.

- Use of interferon or cytarabine within 14 days

- Use of a targeted small-molecule anticancer agent within 14 days

- Use of certain medication that carry a known side effect risk of Torsade de Pointes
- Certain medications that irreversibly inhibit platelet function or anticoagulants

- Prior therapy with dasatinib.